0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis.

      Journal of Clinical Pharmacy and Therapeutics
      Administration, Inhalation, Adrenergic beta-2 Receptor Agonists, administration & dosage, therapeutic use, Albuterol, analogs & derivatives, Bronchodilator Agents, pharmacology, Delayed-Action Preparations, Drug Therapy, Combination, Ethanolamines, Glucocorticoids, Humans, Indans, Pulmonary Disease, Chronic Obstructive, drug therapy, physiopathology, Quinolones, Randomized Controlled Trials as Topic

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

            Inhaled long-acting beta-agonists have been licensed for the treatment of chronic obstructive pulmonary disease (COPD) since the late 1990s, and they improve lung function and symptoms of dyspnoea. However, the evidence that long-acting beta-agonists alone can reduce the rate of COPD exacerbations is not conclusive. This meta-analysis was performed to evaluate their effect on the frequency of exacerbations. MEDLINE, EMBASE, CINAHL and the Cochrane trials database were searched for the review. Randomized controlled trials of greater than or equal to 24weeks' treatment duration comparing long-acting beta-agonists (LABAs) with placebo were reviewed. Studies were pooled to yield odds ratios (ORs) with 95% confidence intervals (CIs). Seventeen randomized controlled trials (11871 randomized subjects) met the inclusion criteria and were selected for analysis. Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. Salmeterol significantly reduced COPD exacerbations with both study arms exposed or not exposed to inhaled corticosteroids (ICS). The summary ORs were 0·79 (95% CI: 0·67-0·92; P<0·01) and 0·80 (95% CI: 0·65-0·99; P=0·04), respectively. However, when both arms were not exposed to ICS, there was no significant reduction in exacerbations with formoterol compared with placebo. The 'summary OR was 0·93 (95% CI: 0·75-1·15; P=0·50). Long-acting beta-agonists reduce the frequency of COPD exacerbations. Salmeterol, formoterol and indacaterol significantly reduced COPD exacerbations compared with placebo. Salmeterol but not formoterol decreased exacerbations significantly in the absence of ICS. © 2011 Blackwell Publishing Ltd.

          Related collections

          Author and article information

          Comments

          Comment on this article